Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:
馬薩諸塞州沃爾瑟姆,2024年11月27日(GLOBE NEWSWIRE)——Apellis Pharmicals, Inc.(納斯達克股票代碼:APLS)今天宣佈,該公司將參加以下12月的投資者會議:
- Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ET
- Citi Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET
- Evercore ISI HealthConx 會議:美國東部時間 2024 年 12 月 4 日星期三上午 9:10 的爐邊談話
- 花旗全球醫療保健大會:美國東部時間2024年12月5日星期四下午 1:00 的爐邊談話
The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event.
會議網絡直播將發佈在公司網站 「投資者與媒體」 欄目的 「活動和演講」 頁面上。網絡直播的重播將在活動結束後的大約 90 天內播出。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
關於 Apellis
Apellis Pharmaceuticals, Inc. 是一家全球生物製藥公司,它將勇敢的科學和同情心相結合,爲患者面臨的一些最具挑戰性的疾病開發改變生活的療法。我們迎來了15年來的第一類新的補體藥物,現在有兩種經批准的針對C3的藥物。其中包括有史以來第一種治療地理萎縮的療法,地理萎縮是全球失明的主要原因。我們認爲,我們才剛剛開始釋放針對嚴重視網膜、罕見和神經系統疾病的C3的潛力。欲了解更多信息,請在推特和領英上訪問或關注我們。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫人:
梅雷迪思·卡亞
meredith.kaya@apellis.com
617.599.8178